0001426332 2023-08-09 2023-08-09 NGM BIOPHARMACEUTICALS INC true 0001426332 8-K/A 2023-08-09 DE 001-38853 26-1679911 333 Oyster Point Boulevard South San Francisco CA 94080 (650) 243-5555 false false false false Common Stock, par value $0.001 per share NGM NASDAQ false NGM Biopharmaceuticals, Inc. (the “Company”) is filing this amendment to its Current Report on Form 8-K filed with the SEC on August 11, 2023 (the “Original Filing”) solely for the purpose of reporting, in accordance with Instruction 2 to Item 5.02 of Form 8-K, the compensation determinations made in connection with Irene Perlich’s appointment as the Company’s principal accounting officer. At the time the Original Filing was made, the terms of such compensation had not yet been determined. This amendment does not otherwise revise the Original Filing in any way.